Biosimulation Market By Software Type (PK/PD Modeling And Simulation, Molecular Modeling And Simulation, PBPK Modeling And Simulation, Toxicity Prediction, Trial Design), By Application (Drug Development, Drug Discovery) - Growth, Future Prospects, Competitive Analysis And Forecast 2017 - 2025

The report titled “Global Biosimulation Market: Growth, Future Prospects, and Competitive Analysis, 2017 -2025” offers strategic insights into the overall biosimulation market along with the market size and estimates for the duration of 2015 to 2025. The said research study covers in-depth analysis of biosimulation market segments based on software type, application and different geographies further segmented by countries. Biosimulation techniques are the newest additions to the drug development industry which is based on simulation of biologic process via computer programs. This technique is widely used to predict the path of drug development and has proven beneficial in reducing patient numbers, time and cost incurred in the entire drug development process, thus proving beneficial for the pharmaceutical industries for its overall growth. Owing to the aforementioned benefits and an increase in awareness, demand and adoption of biosimulation, this market is presumed to have an increased growth in the forecasted period of 2017-2025.

For the purpose of this study, the global biosimulation market is segmented as follows:

  • By Software Type
    • PK/PD Modeling and Simulation Software
    • Molecular Modeling and Simulation Software
    • PBPK Modeling and Simulation Software
    • Toxicity Prediction Software
    • Trial Design Software
    • Other Software’s
  • By Application
    • Drug development
      • Preclinical testing
      • Clinical trials
    • Drug discovery
      • Lead Analysis (Identification & Optimization)
      • Target Analysis (Identification & Optimization)
    • Others

Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective compounded annual growth rates (CAGRs) for the period 2017 to 2025, considering 2016 as the base year.

The geographical segmentation of the global biosimulation market comprised regions such as North America, Europe, Asia-Pacific, Latin America & Middle East and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, Mexico, Saudi Arabia, South Africa, and other countries. Market size and forecast for these segments during 2015 to 2025 and their CAGRs for the period 2017 to 2025 are provided in this report.

The biosimulation market is observed as the most diversified and competitive market comprising large number of players.  The market is dominated by several players, depending on their major competencies. The key players in this market are Certara USA, Inc., Simulation Plus, Inc., Dassault Systems SA, Schrodinger, Inc., Advanced Chemistry Development, Inc., Chemical Computing Group, Inc., Physiomics PLC, Entelos, Inc., Rhenovia Pharma Ltd., Genedata AG, Evidera, Inc., In Silico Biosciences Inc., Oxford Drug Design, Insilico Biotechnology AG, Leadinvent technologies Pvt Ltd. & Leadscope, Inc.

Biosimulation Market

For the purpose of this study, the biosimulation market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Biosimulation Market

Biosimulation provides simulation of biological system thus rendering most beneficial in the clinical trial development thus preventing the risks of drug failures. For the purpose of this study, the global biosimulation market is segmented into regional markets viz., North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Of the aforementioned regions, North America encapsulated the largest share in the biosimulation market. The major factors that drive this predominance in the North American market are increase in drug development initiations, stringent regulatory policies ensuring patient safety and efficacy standards thus raising the demand to pre-analyze the success rate of the molecule before entering clinical trials, rise in number of strategic collaborations between pharmaceutical industries/research institute and in silico developers for simulation based drug development. Asia-Pacific is projected to show a positive growth biosimulation market during the forecast period, 2017-2025. The drivers propelling this market are increasing presence of CRO’s, development of healthcare infrastructure, penetration of healthcare IT and an extensive initiation of research and development activities.

Choose License Type
Published Date:  Nov 2017
Category:  Pharmaceuticals
Report ID:   58787
Report Format:   PDF
Pages:   120
Rating:    4.4 (70)
Connect With Us
24/7 Research Support